|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...2627282930313233343536...6768» |
- marzeptacog alfa (CB 813d) / GC Biopharma
Trial primary completion date: Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia (clinicaltrials.gov) - Dec 24, 2014
P1, N=24, Recruiting, Sponsor: Pfizer
Trial primary completion date: Oct 2014 --> Feb 2015
- | Trial suspension: Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain (clinicaltrials.gov) - Dec 24, 2014
P1/2, N=52, Suspended, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Oct 2014 --> Feb 2015 Recruiting --> Suspended
- ||| carfilzomib / Generic mfg.
P1/2 data: Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma (clinicaltrials.gov) - Dec 24, 2014
P1/2, N=184, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Recruiting --> Suspended Completed --> Active, not recruiting | N=235 --> 184 | Trial primary completion date: Jan 2014 --> Jul 2014
- ||| marizomib (NPI-0052) / Triphase Accelerator Corporation, BMS
P2 data: Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 24, 2014
P1/2, N=100, Active, not recruiting, Sponsor: Triphase Research and Development I Corporation
Completed --> Active, not recruiting | N=235 --> 184 | Trial primary completion date: Jan 2014 --> Jul 2014 Recruiting --> Active, not recruiting
- Erivedge (vismodegib) / Roche
Trial completion, Enrollment change: Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma (clinicaltrials.gov) - Dec 24, 2014
P1, N=50, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=38 --> 50
- Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Trial completion: AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Dec 24, 2014
P2, N=36, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=38 --> 50 Active, not recruiting --> Completed
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial completion, Enrollment change, Trial primary completion date: Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms (clinicaltrials.gov) - Dec 24, 2014
P1, N=93, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=60 --> 93 | Trial primary completion date: Dec 2014 --> Oct 2012
- ||| Clinical data, HEOR: HAMLET: 2-cohort Study of Adult Patients With Severe Hemophilia A in Greece (clinicaltrials.gov) - Dec 19, 2014
P=N/A, N=75, Not yet recruiting, Sponsor: Bayer
- Enrollment open: Study of the Immune Response After Vaccination in Multiple Myeloma Patients (clinicaltrials.gov) - Dec 19, 2014
P=N/A, N=80, Recruiting, Sponsor: Michael A. Thompson, MD, PhD
Active, not recruiting --> Completed | N=60 --> 93 | Trial primary completion date: Dec 2014 --> Oct 2012 Not yet recruiting --> Recruiting
- Kcentra (plasma-derived prothrombin complex concentrate) / CSL Behring
Enrollment open: Study of a Prothrombin Complex Concentrate for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Japanese Subjects (clinicaltrials.gov) - Dec 19, 2014
P3, N=10, Recruiting, Sponsor: CSL Behring
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | bortezomib / Generic mfg., melphalan / Generic mfg.
Trial suspension: Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Dec 19, 2014
P1/2, N=69, Suspended, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Active, not recruiting --> Suspended
- albumin-bound paclitaxel / Generic mfg.
Trial suspension: Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 19, 2014
P2, N=30, Suspended, Sponsor: Mayo Clinic
Active, not recruiting --> Suspended Active, not recruiting --> Suspended
- || ontuxizumab (MORAb-004) / Eisai
Trial initiation date: MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - Dec 19, 2014
P1, N=65, Recruiting, Sponsor: Morphotek
Active, not recruiting --> Suspended Initiation date: Aug 2013 --> Nov 2013
- || Idelvion (albutrepenonacog alfa) / CSL Behring
Trial completion, Trial primary completion date: A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B (clinicaltrials.gov) - Dec 19, 2014
P3, N=27, Completed, Sponsor: CSL Behring
Initiation date: Aug 2013 --> Nov 2013 Active, not recruiting --> Completed | Trial primary completion date: Mar 2016 --> Oct 2014
- ||||||| RiaSTAP (fibrinogen concentrate (human)) / CSL Behring
Trial completion, Surgery: Haemocomplettan® P During Elective Complex Cardiac Surgery (clinicaltrials.gov) - Dec 17, 2014
P2/3, N=120, Completed, Sponsor: Isala
Active, not recruiting --> Completed | Trial primary completion date: Mar 2016 --> Oct 2014 Recruiting --> Completed
- peripheral blood stem cell transplantation / National Cancer Institute
Trial initiation date, Gene therapy: Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma (clinicaltrials.gov) - Dec 17, 2014
P=N/A, N=13, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Completed Initiation date: Oct 2014 --> Feb 2015
- aspirin / Generic mfg., hydroxyurea / Generic mfg.
Enrollment closed, Trial primary completion date: Primary Thrombocythaemia 1 Trial (clinicaltrials.gov) - Dec 17, 2014
P=N/A, N=1600, Active, not recruiting, Sponsor: University of Cambridge
Initiation date: Oct 2014 --> Feb 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2014 --> Apr 2024
- | dacetuzumab (SGN-40) / Pfizer
Trial completion: Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma (clinicaltrials.gov) - Dec 17, 2014
P1, N=44, Completed, Sponsor: Seattle Genetics, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2014 --> Apr 2024 Recruiting --> Completed
- Clinical: FOX-TREG: Study of the Role of Regulator T Cells in the Pathophysiology of Childhood Henoch Schönlein Purpura (clinicaltrials.gov) - Dec 16, 2014
P=N/A, N=120, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
- ||| lenalidomide / Generic mfg., sirolimus / Generic mfg.
Enrollment closed: Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM) (clinicaltrials.gov) - Dec 13, 2014
P1/2, N=53, Active, not recruiting, Sponsor: Indiana University School of Medicine
Recruiting --> Completed Recruiting --> Active, not recruiting
- Simulect (basiliximab) / Novartis
Trial completion: Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer (clinicaltrials.gov) - Dec 13, 2014
P2, N=17, Completed, Sponsor: Indiana University School of Medicine
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- alisertib (MLN8237) / Puma, Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Dec 12, 2014
P2, N=50, Recruiting, Sponsor: Kristie Blum
Active, not recruiting --> Completed Trial primary completion date: Jun 2014 --> Dec 2015
- | fludarabine IV / Generic mfg., busulfan / Generic mfg.
Enrollment change, Trial primary completion date: Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen (clinicaltrials.gov) - Dec 12, 2014
P2, N=22, Active, not recruiting, Sponsor: University of Michigan Cancer Center
Trial primary completion date: Jun 2014 --> Dec 2015 N=40 --> 22 | Trial primary completion date: Jun 2014 --> Dec 2012
- | bendamustine / Generic mfg.
New P1 trial: Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma (clinicaltrials.gov) - Dec 11, 2014
P1, N=12, Not yet recruiting, Sponsor: Thomas Jefferson University
- Enrollment change, Trial termination, Trial primary completion date: Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant (clinicaltrials.gov) - Dec 10, 2014
P2, N=35, Terminated, Sponsor: Greg Monohan
N=40 --> 22 | Trial primary completion date: Jun 2014 --> Dec 2012 N=70 --> 35 | Suspended --> Terminated | Trial primary completion date: Oct 2014 --> Jun 2014; Research cancelled following interim analysis
- Rituxan (rituximab) / Roche
Trial primary completion date: PLRG4: First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. (clinicaltrials.gov) - Dec 10, 2014
P3, N=250, Active, not recruiting, Sponsor: Polish Lymphoma Research Group
N=70 --> 35 | Suspended --> Terminated | Trial primary completion date: Oct 2014 --> Jun 2014; Research cancelled following interim analysis Trial primary completion date: Jun 2014 --> May 2015
- Enrollment change, Trial termination, Trial primary completion date: Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant (clinicaltrials.gov) - Dec 10, 2014
P1, N=24, Terminated, Sponsor: Vanderbilt University
Trial primary completion date: Jun 2014 --> May 2015 N=50 --> 24 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Dec 2014; PI leaving institution
- New P1 trial: A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency (clinicaltrials.gov) - Dec 10, 2014
P1, N=12, Recruiting, Sponsor: ProMetic BioTherapeutics, Inc
- |||||| Tavalisse (fostamatinib) / Rigel
Enrollment open: A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Dec 10, 2014
P3, N=75, Recruiting, Sponsor: Rigel Pharmaceuticals
N=50 --> 24 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Dec 2014; PI leaving institution Not yet recruiting --> Recruiting
- | bortezomib / Generic mfg., cyclophosphamide / Generic mfg., thalidomide / Generic mfg.
Enrollment open, Trial primary completion date: Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04) (clinicaltrials.gov) - Dec 10, 2014
P3, N=340, Recruiting, Sponsor: Nantes University Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2016 --> Jun 2015
- Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial completion, Enrollment change, Trial primary completion date, IO biomarker: Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma (clinicaltrials.gov) - Dec 10, 2014
P2, N=8, Completed, Sponsor: Tufts Medical Center
Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2016 --> Jun 2015 Active, not recruiting --> Completed | N=14 --> 8 | Trial primary completion date: Sep 2014 --> Jan 2013
- Trial completion, Trial primary completion date: A Phase II Study of Umbilical Cord Blood Transplantation (clinicaltrials.gov) - Dec 10, 2014
P2, N=7, Completed, Sponsor: Tufts Medical Center
Active, not recruiting --> Completed | N=14 --> 8 | Trial primary completion date: Sep 2014 --> Jan 2013 Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jul 2013
- bortezomib / Generic mfg., bendamustine / Generic mfg.
Trial primary completion date: Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma (clinicaltrials.gov) - Dec 9, 2014
P2, N=25, Active, not recruiting, Sponsor: New York University School of Medicine
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jul 2013 Trial primary completion date: Dec 2013 --> Feb 2015
- fresolimumab (GC 1008) / Sanofi
Trial termination: Anti-TGF-beta Therapy in Patients With Myelofibrosis (clinicaltrials.gov) - Dec 9, 2014
P1, N=3, Terminated, Sponsor: John Mascarenhas
Trial primary completion date: Dec 2013 --> Feb 2015 Completed --> Terminated; Early termination when the drug was no longer made available by the pharmaceutical company due to unanticipated management and administrative decisions.
- |||| Empliciti (elotuzumab) / AbbVie, BMS
Enrollment open: Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 9, 2014
P2, N=150, Recruiting, Sponsor: Bristol-Myers Squibb
Completed --> Terminated; Early termination when the drug was no longer made available by the pharmaceutical company due to unanticipated management and administrative decisions. Active, not recruiting --> Recruiting
- |||| Promacta (eltrombopag) / Novartis
Trial primary completion date: EXTEND (Eltrombopag Extended Dosing Study) (clinicaltrials.gov) - Dec 7, 2014
P3, N=302, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Recruiting Trial primary completion date: Jul 2014 --> Dec 2014
- cyclophosphamide / Generic mfg., carfilzomib / Generic mfg.
Clinical: A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma (clinicaltrials.gov) - Dec 6, 2014
P1, N=38, Recruiting, Sponsor: Academic Myeloma Consortium
Trial primary completion date: Jul 2014 --> Dec 2014 Trial primary completion date: Nov 2014 --> Dec 2017
- | dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Combination therapy: A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Dec 6, 2014
P2, N=26, Active, not recruiting, Sponsor: Celgene Corporation
Trial primary completion date: Nov 2014 --> Dec 2017 N=20 --> 26
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma, Rituxan (rituximab) / Roche
Enrollment open, Trial initiation date, Trial primary completion date, Combination therapy: CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Dec 6, 2014
P1, N=14, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
N=20 --> 26 Not yet recruiting --> Recruiting | Initiation date: Aug 2014 --> Dec 2014 | Trial primary completion date: Aug 2016 --> Dec 2016
- bortezomib / Generic mfg.
Enrollment closed, Trial primary completion date: Bortezomib Consolidation Trial (clinicaltrials.gov) - Dec 6, 2014
P2, N=45, Active, not recruiting, Sponsor: University College, London
Not yet recruiting --> Recruiting | Initiation date: Aug 2014 --> Dec 2014 | Trial primary completion date: Aug 2016 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Dec 2014
- Enrollment change, Trial withdrawal, Trial primary completion date: Changes in Bleeding and Clotting During the Menstrual Cycle (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=0, Withdrawn, Sponsor: The University of Texas Health Science Center, Houston
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Dec 2014 N=40 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2014 --> May 2011
- Trial completion, Enrollment change, HEOR: Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=381, Completed, Sponsor: Novo Nordisk A/S
N=40 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2014 --> May 2011 Enrolling by invitation --> Completed | N=300 --> 381
- ||| bortezomib / Generic mfg., melphalan / Generic mfg.
Enrollment closed: Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Dec 5, 2014
P1/2, N=69, Active, not recruiting, Sponsor: Mayo Clinic
Enrolling by invitation --> Completed | N=300 --> 381 Recruiting --> Active, not recruiting
- | albumin-bound paclitaxel / Generic mfg.
Enrollment closed: Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 5, 2014
P2, N=30, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment closed, Combination therapy: ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Dec 5, 2014
P2, N=35, Active, not recruiting, Sponsor: Vejle Hospital
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | lenalidomide / Generic mfg.
New P1/2 trial: Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia (clinicaltrials.gov) - Nov 28, 2014
P1/2, N=17, Active, not recruiting, Sponsor: University Hospital, Lille
- | anagrelide CR (GALE-401) / SELLAS Life Sciences
Enrollment closed: A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders (clinicaltrials.gov) - Nov 28, 2014
P2, N=20, Active, not recruiting, Sponsor: Galena Biopharma, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment closed, Trial primary completion date, Post-transplantation: Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Nov 28, 2014
P0, N=20, Active, not recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Oct 2014
- Clinical: Thrombin Generation Numerical Models Validation in Haemophilic Case (clinicaltrials.gov) - Nov 25, 2014
P=N/A, N=40, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
- Calsed (amrubicin) / Sumitomo Pharma, BMS
Trial primary completion date, Combination therapy: Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 25, 2014
P1/2, N=42, Active, not recruiting, Sponsor: Michaela Liedtke
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Oct 2014 Trial primary completion date: Oct 2014 --> Jul 2014